The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The administration of single oral doses of delta‐9‐tetrahydrocannabinol (THC) to patients with cancer pain demonstrated a mild analgesic effect. At a dose of 20 mg, however, THC induced side effects that would prohibit its therapeutic use including somnolence, dizziness, ataxia, and blurred vision. Alarming adverse reactions were also observed at this dose. THC, 10 mg, was well tolerated and, despite its sedative effect, may have analgesic potential.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Keele, K. D. (1948) · The Lancet · doi:10.1016/s0140-6736(48)91787-5 · Cited by 241
Ames, F. (1958) · Journal of Mental Science · doi:10.1192/bjp.104.437.972 · Cited by 184
Snyder, S. H. (1971) · Medical Entomology and Zoology · Cited by 30
Cited by
Items 201–300 of 376
Whitcomb, B. P., Lutman, C. V., Pearl, M. L., Medlin, E. E., Prendergast, E. N., Robison, K. M., & Burke, W. M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.013 · Cited by 23
Update on cannabis and cannabinoids for cancer pain
Chung, M. J., Kim, H. K., & Abdi, S. (2020) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000934 · Cited by 26
“05) with no significant difference between THC and codeine [68].”
BackgroundOrofacial Pain and Neurosensory Disorders and Dysfunction in Cancer Patients
Clark, G. T., & Ram, S. (2008) · Dental Clinics of North America · doi:10.1016/j.cden.2007.09.003 · Cited by 22
Biomedical benefits of cannabinoids?
Ashton, C. H. (1999) · Addiction Biology · doi:10.1080/13556219971623 · Cited by 29
“Sedation common with THC Noyes et al.75 36 patients with cancer pain Oral THC 10 and 20 mg. Oral codeine 60 and 120 mg, or placebo THC 20 mg and codeine 120 mg gave equivalent and significant pain relief compared to placebo.”
BackgroundHasan, N., Imran, M., Sheikh, A., Saad, S., Chaudhary, G., Jain, G. K., Kesharwani, P., & Ahmad, F. J. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2056188 · Cited by 23
“[86] conducted a trial in 10 patients, and the investigation revealed that the analgesic effect of THC at 15–20mg dose was superior to placebo.”
BackgroundOstadhadi, S., Rahmatollahi, M., Dehpour, A. R., & Rahimian, R. (2014) · Phytotherapy Research · doi:10.1002/ptr.5265 · Cited by 21
“Leading exploratory trials showed that the inhibitory effect of THC for cancer pain is related with sedation and ‘mental clouding’ in most patients (Noyes et al., 1975a; Noyes et al., 1975b).”
BackgroundCannabis: Time for Scientific Evaluation of This Ancient Remedy?
Sharpe, P., & Smith, G. (2000) · Anesthesia & Analgesia · doi:10.1097/00000539-200002000-00001 · Cited by 21
“(29,30), in the mid 1970s, showed that D9THC had analgesic potency similar to that of codeine, but these studies were, however, based on small numbers of patients and did not use whole cannabis extract.”
BackgroundScotopic vision in the monkey is modulated by the G protein-coupled receptor 55
Bouskila, J., Harrar, V., Javadi, P., Casanova, C., Hirabayashi, Y., Matsuo, I., Ohyama, J., Bouchard, J., & Ptito, M. (2016) · Visual Neuroscience · doi:10.1017/s095252381600002x · Cited by 23
“…lead to an increase in glare recovery for low contrast stimuli (Adams et al., 1978 ), a reduction in Vernier and Snellen acuities (Kiplinger et al., 1971 ; Adams et al., 1975 ), blurred vision (Noyes et al., 1975 ), and changes in color discrimination and photosensitivity (Dawson et al., 1977 ).”
BackgroundMcCarberg, B. H. (2007) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/j354v21n03_04 · Cited by 26
Cannabinoid Interaction with Brain Reward Systems
Gardner, E. L. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-710-9_19 · Cited by 22
Niyangoda, D., Aung, M. L., Qader, M., Tesfaye, W. H., Bushell, M., Chiong, F. J. K., Tsai, D., Ahmad, D., Samarawickrema, I., Sinnollareddy, M., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13111023 · Cited by 29
Therapeutic Applications for Agents that Act at CB1 and CB2 Receptors
Pertwee, R. G., & Thomas, A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-503-9_13 · Cited by 24
Cannabinoid Receptors CB1 and CB2 Modulate the Electroretinographic Waves in Vervet Monkeys
Bouskila, J., Harrar, V., Javadi, P., Beierschmitt, A., Palmour, R. M., Casanova, C., Bouchard, J., & Ptito, M. (2016) · Neural Plasticity · doi:10.1155/2016/1253245 · Cited by 21
Cannabinoid-Based Medicines for Neurological Disorders—Clinical Evidence
Wright, S. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0003-4 · Cited by 22
Effects of 20 mg oral Δ9‐tetrahydrocannabinol on the olfactory function of healthy volunteers
Walter, C., Oertel, B. G., Ludyga, D., Ultsch, A., Hummel, T. R., & Lötsch, J. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12415 · Cited by 19
The Pharmacotherapy of Chronic Pain
Lynch, M. E. (2008) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2008.04.001 · Cited by 18
Understanding and Managing Patients with Chronic Pain
Szumita, R. P., Szumita, P. M., & Just, N. (2010) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2010.07.005 · Cited by 16
Marijuana (Cannabis) as Medicine
Hollister, L. E. (2001) · Journal of Cannabis Therapeutics · doi:10.1300/j175v01n01_02 · Cited by 19
“The 10 mg dose, which was better tolerated, was less effective than either dose of codeine (Noyes et al. 1975).”
BackgroundPharmacologie des dérivés cannabinoïdes : applications au traitement de la douleur ?
Beaulieu, P., & Rice, A. S. C. (2002) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/s0750-7658(02)00663-9 · Cited by 19
Cannabis: dangers and possible uses.
Ashton, C. H. (1987) · BMJ · doi:10.1136/bmj.294.6565.141 · Cited by 16
The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine
Skórzewska, M., & Gęca, K. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01589-4 · Cited by 19
“These effects tend to be dose-dependent, with higher doses of cannabis often associated with a greater frequency and intensity of AEs [40, 67, 68].”
Do cannabinoids have a role in cancer pain management?
Farquhar-Smith, W. P. (2009) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283260612 · Cited by 15
An Integrated Review of Cannabis and Cannabinoids in Adult Oncologic Pain Management
Shin, S. J., Mitchell, C., Mannion, K., Smolyn, J., & Meghani, S. H. (2018) · Pain Management Nursing · doi:10.1016/j.pmn.2018.09.006 · Cited by 18
Köstenberger, M., Nahler, G., Jones, T., Neuwersch-Sommeregger, S., & Likar, R. (2021) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-021-10010-x · Cited by 20
Endogenes Cannabinoidsystem: Einfluss auf neuronale Plastizität und Schmerzgedächtnis
Azad, S. C., Huge, V., Schöps, P., Hilf, C., Beyer, A., Dodt, H., Rammes, G., & Zieglgänsberger, W. (2004) · Der Schmerz · doi:10.1007/s00482-004-0342-2 · Cited by 19
Recent discoveries in the search for non‐opiate analgetics
Johnson, M. R., & Milne, G. M. (1980) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.5570170841 · Cited by 15
Therapeutic potential of cannabinoids.
Bateman, D. N., & Rawlins, M. D. (1982) · BMJ · doi:10.1136/bmj.284.6324.1211-a · Cited by 15
Cannabinoids for Pain Management
Thaler, A., Gupta, A., & Cohen, S. P. (2011) · Advances in psychosomatic medicine · doi:10.1159/000324070 · Cited by 15
Vadivelu, N., Kai, A., Kodumudi, G., Sramcik, J., & Kaye, A. D. (2018) · Current Pain and Headache Reports · doi:10.1007/s11916-018-0656-x · Cited by 15
DeVuono, M. V., Caprara, O. L., Petrie, G. N., Limebeer, C. L., Rock, E. M., Hill, M. N., & Parker, L. A. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0083 · Cited by 18
Lee, D., Vandrey, R. G., Mendu, D. R., Anizan, S., Milman, G., Murray, J. A., Barnes, A. J., & Huestis, M. A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.207316 · Cited by 14
DeVuono, M. V., Hrelja, K. M., Sabaziotis, L., Rajna, A., Rock, E. M., Limebeer, C. L., Mutch, D. M., & Parker, L. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.08.039 · Cited by 16
“Moreover, humans report nausea and vomiting as a side effect when given high doses of THC (Frytak et al., 1979; Noyes et al., 1975; Vaziri et al., 1981) and synthetic cannabinoids (i.e. “Spice”) https://doi.org/10.1016/j.neuropharm.2018.08.039 Received 19 June 2018; Received in revised form 24…”
InfluentialRahman, S., Ayyagari, A., Dutta, D., Kumar, V., Kim, J., Jan, A. T., & Minakshi, R. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.01.005 · Cited by 34
“THC has been used as antiemetic and analgesic in chemotherapy receiving patients (Carey et al., 1983; Noyes et al., 1975).”
DeVuono, M. V., Caprara, O. L., Sullivan, M. T., Bath, A., Petrie, G. N., Limebeer, C. L., Rock, E. M., Hill, M. N., & Parker, L. A. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05529-5 · Cited by 15
“There are several reports that the main intoxicating component of the cannabis plant Δ(9)-tetrahydrocannabinol (THC) (Mechoulam and Gaoni 1965) produces dose-dependent acute nausea and vomiting in humans (Noyes et al. 1975; Frytak et al. 1979; Vaziri et al. 1981), and laboratory animals (Scheckel et al.”
BackgroundAn analgesic role for cannabinoids
Vaughan, C. W., & Christle, M. J. (2000) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2000.tb125638.x · Cited by 13
Should oncologists trust cannabinoids?
Creangă-Murariu, I., Filipiuc, L.-E., Cuciureanu, M. D., Tamba, B.-I., & Alexa‐Stratulat, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1211506 · Cited by 13
“compared THC to codeine (Noyes et al., 1975a; Noyes et al., 1975b) with good outcomes despite notable side-effects at high doses.”
BackgroundWalter, C., Oertel, B. G., Felden, L., Nöth, U., Vermehren, J., Deichmann, R., & Lötsch, J. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2331-2 · Cited by 13
“Present findings of a reduced olfactory function as a drug of THC reflect the dosage of 20 mg, which is recommended for pain treatment [56].”
Psychologic effects of oral delta-9-tetrahydrocannabinol in advanced cancer patients
Noyes, R., Brunk, S. F., Avery, D., & Canter, A. (1976) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(76)80008-9 · Cited by 13
Self-citationHigh hopes for cannabinoid analgesia
Watts, G. (2004) · BMJ · doi:10.1136/bmj.38168.627292.0b · Cited by 14
Cancer pain assessment and treatment curriculum guidelines
Ad Hoc Committee on Cancer Pain of the American Society of Clinical Oncology (1993) · Supportive Care in Cancer · doi:10.1007/bf00366898 · Cited by 13
Compton, D. M., Harris, L. S., Lichtman, A. H., & Martin, B. R. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-60963-3_3 · Cited by 16
Gorzo, A., Havasi, A. D., Spînu, Ș., Oprea, A. L., Burz, C. C., & Sur, D. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175036 · Cited by 17
“Moreover, side effects are difficult to assess, especially in patients with advanced cancer, who are likely to take countless concomitant medications [30,85].”
BackgroundThe Exploration of Cannabis and Cannabinoid Therapies for Migraine
Chandwani, B. P., Bradley, B. A., Pace, A., Buse, D. C., Singh, R., & Kuruvilla, D. E. (2023) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01144-z · Cited by 13
Does cannabis alleviate tinnitus? A review of the current literature
Narwani, V., Bourdillon, A. T., Nalamada, K., Manes, R. P., & Hildrew, D. M. (2020) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.479 · Cited by 12
“On the contrary, evidence suggests that cannabinoids may induce or worsen tinnitus.(71,79,90,99) As high quality prospective research for the effect of cannabis on tinnitus is lacking, evidence can neither support nor refute the use of cannabis in controlling symptoms of tinnitus.”
BackgroundSystematic Review of the Use of Phytochemicals for Management of Pain in Cancer Therapy
Harrison, A. M., Heritier, F., Childs, B. G., Bostwick, J. M., & Dziadzko, M. A. (2015) · BioMed Research International · doi:10.1155/2015/506327 · Cited by 13
Cannabinoids in Cancer Pain Management
Huskey, A. (2006) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/j354v20n03_11 · Cited by 12
Going Beyond Efficacy: Supportive Care and Addressing the Toxicity of Systemic Therapy
Verma, S. (2008) · Current Oncology · doi:10.3747/co.2008.175 · Cited by 12
Appraisal of Codeine as an Analgesic in Older Patients*
Jochimsen, P. R., & YES, R. N. (1978) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1978.tb03337.x · Cited by 12
Pharmacologic management of chronic pain
Portenoy, R. K. (1990) · Elsevier eBooks · doi:10.1016/b978-0-407-01124-3.50017-4 · Cited by 12
Tetrahydrocannabinols: potential cannabimimetic agents for cancer therapy
Prateeksha, P., Sharma, V. K., Singh, S. M., Sharma, M., Diwan, D., Hesham, A. E., Guleria, S., Nguyen, Q. D., Gupta, V. K., & Singh, B. N. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10078-2 · Cited by 12
“However, all patients ( n = 10) experienced substantial sedation and mental clouding at the higher dose (20 mg) [67].”
BackgroundAnalgesic Effect of the Synthetic Cannabinoid CT-3 on Chronic Neuropathic Pain
Karst, M., Salim, K., BURSTEIN, S. H., Conrad, I., Hoy, L., & Schneider, U. (2016) · Cited by 11
Pertwee, R. G. (2008) · Springer eBooks · doi:10.1007/978-0-387-76678-2_38 · Cited by 14
Grond, S., & Radbruch, L. (1998) · Der Schmerz · doi:10.1007/s004820050137 · Cited by 11
Rajapakse, T., & Gantenbein, A. R. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-12-823357-3.00001-x · Cited by 12
Bondok, M., Nguyen, A. X.-L., Landó, L., & Wu, A. Y. (2024) · Clinical ophthalmology · doi:10.2147/opth.s501494 · Cited by 12
Giordano, G., Martin‐Willett, R., Gibson, L. P., Camidge, D. R., Bowles, D. W., Hutchison, K. E., & Bryan, A. D. (2023) · Exploration of Medicine · doi:10.37349/emed.2023.00138 · Cited by 15
Bachhuber, M. A., Arnsten, J. H., Starrels, J. L., & Cunningham, C. O. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0051 · Cited by 9
Marmor, J. B. (1998) · Europe PMC (PubMed Central) · Cited by 11
The uptake ofΔ9-tetrahydrocannabinol in choroid plexus and brain cortexin vitro andin vivo
Agnew, W. F., Rumbaugh, C. L., & Cheng, J. T. (1976) · Brain Research · doi:10.1016/0006-8993(76)90535-7 · Cited by 10
Prescribing Cannabinoids for Multiple Sclerosis: Current Issues
Pertwee, R. G. (1999) · CNS Drugs · doi:10.2165/00023210-199911050-00001 · Cited by 11
Fields, H. L., & Meng, I. D. (1998) · Nature Medicine · doi:10.1038/1995 · Cited by 10
Jones, R. T. (1978) · Springer eBooks · doi:10.1007/978-1-4684-3186-5_7 · Cited by 11
Bimonte, S., Nocerino, D., SCHIAVO, D., CRISCI, M., Cascella, M., & Cuomo, A. (2024) · Anticancer Research · doi:10.21873/anticanres.16883 · Cited by 13
“Results indicated that pain was significantly relieved only in patients treated with THC and at high doses of codeine compared with placebo (46).”
BackgroundAggressive Driving Behaviours in Cannabis Users. The Influence of Consumer Characteristics
Ortiz‐Peregrina, S., Ortíz, C., & Anera, R. G. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18083911 · Cited by 9
“These results are in line with previous findings that suggest blurred vision in cannabis users [17,51].”
ResultPhysiological and Pharmacological Interactions of Marihuana (THC) with Drugs and Anesthetics
Sutin, K. M., & Nahas, G. G. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-710-9_26 · Cited by 9
Formukong, E. A., EVANS, A. T., Evans, F. J., & GARLAND, L. G. (1991) · Phytotherapy Research · doi:10.1002/ptr.2650050606 · Cited by 9
PHARMACOLOGICAL SIMILARITIES AND INTERACTIONS BETWEEN CANNABIS AND OPIOIDS
KAYMAKÀALAN, S. (1979) · Elsevier eBooks · doi:10.1016/b978-0-08-023759-6.50050-0 · Cited by 9
Cannabinoids and Pain Control in the Periphery
McDougall, J. J. (2009) · Wiley eBooks · doi:10.1002/9780470522226.ch13 · Cited by 10
Transmucosal delivery of the medical Cannabis oil via a nanoemulsion formulation
d’Angelo, I., Provenzano, R., Florio, E., Lombardi, A., Trama, U., Ungaro, F., Quaglia, F., & Miro, A. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104004 · Cited by 8
A Case of Cannabinoid Rotation in a Young Woman With Chronic Cystitis
Krenn, H., Daha, L. K., Oczenski, W., & Fitzgerald, R. D. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00601-2 · Cited by 8
Pharmacologic Approaches to the Control of Cancer Pain
Portenoy, R. K. (1990) · Journal of Psychosocial Oncology · doi:10.1300/j077v08n02_05 · Cited by 8
Phosphorene: A novel nanomaterial revolutionizing biomedicine
Islam, M. S., Islam, M. T., & Hossain, M. R. (2024) · JCIS Open · doi:10.1016/j.jciso.2024.100124 · Cited by 8
Mücke, M., Carter, C., Cuhls, H., Prüß, M. S., Radbruch, L., & Häuser, W. (2016) · Der Schmerz · Cited by 7
Richet, E., Ferret, L., Gaboriau, L., Charpentier, P., Dujardin, L., Fulcrand, J., & Boursier, A. (2022) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2022.12.005 · Cited by 7
Lenk, R., & Likar, R. (2008) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-008-0619-7 · Cited by 7
“Die St€arke von THC bei der Behandlung chronischer Schmerzen d€urfte vor allem als Co-Analgetikum zu sehen sein – nicht nur aufgrund seiner erw€ahnten Codein-€aquivalenten analgetischen Potenz.”
BackgroundInfluentialOelen, Y., Revenberg, S., de Vos‐Geelen, J., van Geel, R. M. J. M., Schoenmaekers, J. J. A. O., Everdingen, M. H. J. V. D. B.-V., & Iersel, L. V. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04085-z · Cited by 9
Cannabis use amongst tinnitus patients: Consumption patterns and attitudes
Mavedatnia, D., Levin, M., Lee, J. W., Hamour, A. F., Dizon, K., & Le, T. (2023) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1186/s40463-022-00603-8 · Cited by 8
Tarasiuk, A., Mirocha, G., & Fichna, J. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01146-4 · Cited by 6
Therapeutic properties of cannabinoid drugs and marijuana in several disorders: A narrative review
Alvarado, R. N., Dirección General Adjunta de Políticas y Programas contra las Adicciones, C. N. C. L. A., Sánchez, R. M. D. C., Salcedo, V. V., Dirección General de Políticas y Programas contra las Adicciones, C. N. C. L. A., & Departamento de Investigación Clínica, I. N. D. P. R. D. L. F. M. (2017) · Salud Mental · doi:10.17711/sm.0185-3325.2017.014 · Cited by 6
HEALTH ASPECTS OF CANNABIS USE
Hollister, L. E. (1984) · Elsevier eBooks · doi:10.1016/b978-0-12-044620-9.50006-3 · Cited by 6
Robson, P. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.2.164 · Cited by 8
Cannabinoides y conducta adictiva
Navarro, M., & de Fonseca, F. R. (2000) · Adicciones · doi:10.20882/adicciones.674 · Cited by 11
Cheah, I., Hunter, J., Gelissen, I. C., Chan, W.-J. J., & Harnett, J. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-09087-w · Cited by 7
A FAAH-fetched approach to treat osteoarthritis pain
Lichtman, A. H., & Chapman, V. (2011) · Pain · doi:10.1016/j.pain.2011.02.034 · Cited by 5
“THC has long been known to reduce cancer pain, although this action is accompanied by sensorimotor and cognitive side effects [7,8].”
Backgroundde Barros, G. A. M., Pos, A. M., Sousa, Â. M., Pereira, C. L., Nobre, C. D. D. A., Palmeira, C. C. D. A., Caruy, C. A. A., Munhoz, D. C., Kraychete, D. C., Bergamaschi, E. C. Q. A., et al. (2024) · Brazilian Journal of Anesthesiology (English Edition) · doi:10.1016/j.bjane.2024.844513 · Cited by 8
“18 Despite these promising results, subsequent randomized clinical trials failed to replicate the fi ndings of the study.”
BackgroundModulation of Pain by Endocannabinoids in the Periphery
Uhelski, M. L., Khasabova, I. A., & Simone, D. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79673 · Cited by 6
“Two small clinical evaluations of the efficacy of (−)Δ9-tetrohydrocannabinol (THC), the main psychoactive compound of the cannabis plant, reported pain relief comparable to codeine [39, 40].”
BackgroundClearing The Smoke On Cannabis
Meducator, T., Cui, E., & Rayner, D. G. (2019) · The Meducator · doi:10.15173/m.v1i35.2207 · Cited by 5
Ayoobi, A., & Choi, H. W. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48020204 · Cited by 6
“For instance, THC, a primary cannabinoid, demonstrates analgesic effects comparable to codeine, though its use is limited by side effects such as sedation and mental disturbances [60,61].”
Varadpande, M., Erridge, S., Aggarwal, A., Cowley, I., Evans, L., Clarke, E., McLachlan, K., Coomber, R., Rucker, J., Platt, M. W., et al. (2025) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2025.2457101 · Cited by 6
“Additionally, higher THC doses led to greater odds of reaching an MCID for BPI-Severity.”
InfluentialState of the science: cannabis and cannabinoids in palliative medicine—the potential
Roychoudhury, P., Kapoor, A. K., Walsh, D., Cortés, H., & Clarke, H. A. (2021) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2021-002888 · Cited by 6
The Endocannabinoid System and the Therapeutic Potential of Cannabinoids
Martin, B. R. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-947-9_6 · Cited by 6
The effects of Δ9 THC on cutaneous sensitivity and its relation to personality
Libman, E., & Stern, M. H. (1985) · Personality and Individual Differences · doi:10.1016/0191-8869(85)90106-0 · Cited by 4
Long Term Administration of Cannabis sativa Reduces Food, Water Intake and Body Weight in Mice
Okon, V. E., Ao, O., Nna, V. U., & Ee, O. (2014) · Cited by 4
Going Beyond Efficacy: Strategies for Cancer Pain Management
Myers, J., & Shetty, N. (2008) · Current Oncology · doi:10.3747/co.v15i0.201 · Cited by 14
The use of cannabinoids in palliative medicine
Nelson, K. A., & Walsh, D. (1998) · Progress in Palliative Care · doi:10.1080/09699260.1998.11746811 · Cited by 4
Chapter 3: Narcotic Antagonists and Analgesics
Milne, G. M., & Johnson, M. R. (1976) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61386-x · Cited by 4
Cannabis: Finally a therapeutic agent?
Hollister, L. E. (1983) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(83)90075-3 · Cited by 4
Cannabinoids in pain and palliative care medicine – hope or dope?
Kraft, B., & Kress, H. G. (2009) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-009-0148-0 · Cited by 2
Palliative Care and Cancer Pain
Prommer, E., Jacobs, P., & Mehta, A. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-72216-2.00007-7 · Cited by 3
Attitudes and Beliefs About the Use of Cannabis for Symptom Control in a Palliative Population
Gallagher, R. E., Best, J. A., Fyles, G., Hawley, P., & Yeomans, W. (2003) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n02_04 · Cited by 3
“In humans, there is promising data regarding cancer pain (Noyes et al. 1975a; Noyes et al. 1975b; Staquet et al. 1978) and neuropathic pain (Pertwee 2002; Rice 2001).”
Background
Metadata
- Authors
- Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A.
- Affiliations
- University of Iowa (US)
- ORCID
- Avery, David H.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1975-07
- Volume
- 18
- Issue
- 1
- Pages
- 84-89
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2415446085
- Cited by
- 378
- References
- 4
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 15 · 2023: 14 · 2022: 20 · 2021: 10 · 2020: 16 · 2019: 10 · 2018: 18 · 2017: 11 · 2016: 15 · 2015: 7 · 2014: 11 · 2013: 8 · 2012: 11
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- delta-9-tetrahydrocannabinol, codeine, analgesia, cancer pain, oral administration, adverse drug reactions, sedation, dose-response relationship, drug tolerance
- MeSH terms
- Analgesics, Aspirin, Cannabis, Clinical Trials as Topic, Codeine, Drug Therapy, Combination, Female, Humans, Male, Phytotherapy, Middle Aged, Neoplasms, Pain, Palliative Care, Placebos, Dextropropoxyphene, Dronabinol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.